• 1
    Borrelli O, Bascietto C, Viola F et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 2004; 36: 3427.
  • 2
    Lichtenstein GR. Approach to steroid-dependent and steroid-refractory Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2001; 33 (Suppl. 1): S2735.
  • 3
    Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006; 4: 62130.
  • 4
    Yang Y-X, Lichtenstein GR. Corticosteroids in Crohn's disease. Am. J. Gastroenterol. 2002; 97: 80323.
    Direct Link:
  • 5
    Baldassano R, Braegger CP, Escher JC et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 2003; 98: 8338.
    Direct Link:
  • 6
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 3602.
  • 7
    Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology 2000; 119: 113247.
  • 8
    De Ridder L, Escher JC, Bouquet J et al. Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands. J. Pediatr. Gastroenterol. Nutr. 2004; 39: 4652.
  • 9
    Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2006; 42: 405.
  • 10
    Cezard J-P, Nouaili N, Talbotec C et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 6326.
  • 11
    Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 86373; quiz 1165–6.
  • 12
    Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J. Pediatr. 2000; 137: 1926.
  • 13
    Lamireau T, Cezard J-P, Dabadie A et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm. Bowel Dis. 2004; 10: 74550.
  • 14
    Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. 2001; 35: 8238.
  • 15
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am. J. Gastroenterol. 2003; 98: 10411.
    Direct Link:
  • 16
    De Ridder L, Benninga MA, Taminiau JAJM, Hommes DW, Van Deventer SJH. Infliximab use in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007; 45: 314.
  • 17
    Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 84953.
  • 18
    Mackey AC, Green L, Liang L-C, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007; 44: 2657.
  • 19
    Wei SZ, Liu TH, Wang DT, Cao JL, Luo YF, Liang ZY. Hepatosplenic gammadelta T-cell lymphoma. World J. Gastroenterol. 2005; 11: 372934.
  • 20
    Hyams J, Markowitz J, Otley A et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J. Pediatr. Gastroenterol. Nutr. 2005; 41: 41621.
  • 21
    Loonen HJ, Griffiths AM, Merkus MP, Derkx HH. A critical assessment of items on the Pediatric Crohn's Disease Activity Index. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 905.
  • 22
    Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999; 116: 52731.
  • 23
    Afzal NA, Ozzard A, Keady S, Thomson M, Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn's Disease. Dig. Dis. Sci. 2007; 52: 332933.
  • 24
    Walters TD, Gilman AR, Griffiths AM. Infliximab therapy restores normal growth in children with chronically active severe Crohn disease refractory to immunomodulatory therapy. J. Pediatr. Gastroenterol. Nutr. 2005; 40: 646.
  • 25
    Diamanti A, Basso MS, Gambarara M et al. Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn's disease patients. Int. J. Colorectal. Dis. 2009; 24: 1925.
  • 26
    D'Haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 102934.
  • 27
    Friesen CA, Calabro C, Christenson K et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2004; 39: 2659.
  • 28
    Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007; 96: 12830.
  • 29
    Jacobstein DA, Markowitz JE, Kirschner BS et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. 2005; 11: 4426.
  • 30
    Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment. Pharmacol. Ther. 2003; 17: 7584.
  • 31
    Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 32
    Colombel J-F, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 1931.
  • 33
    Palm Ø, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J. Rheumatol. 2005; 32: 17559.